AndhraNews.net
Home » Features » Health » American Society of Hematology

American Society of Hematology


About American Society of Hematology

American Society of Hematology is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

The 50th Annual Meeting of the American Society of Hematology was held in San Francisco, CA in December 2008.

American Society of Hematology in News

Novimmune Abstract Selected for the "Best of ASH" at the 2015 Annual Meeting of the American Society of Hematology (ASH)

Clinical Trial Results for Actimab-A Presented at the 57th American Society of Hematology Annual Meeting
NEW YORK, NY--(Marketwired - December 08, 2015) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that Dr

New data presented at ASH show Elocta® and Alprolix® may help control target joint bleeds in people with haemophilia A and B
Orlando, Florida, USA, 8 December 2015

Medigene AG: Promising data from Phase I/II IIT and Compassionate Use Programme with dendritic cell vaccines in AML presented at ASH Annual Meeting 2015
Medigene AG /Medigene AG: Promising data from Phase I/II IIT and Compassionate Use Programme with dendritic cell vaccines in AML presented at ASH Annual Meeting 2015 . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
Novartis International AG /Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product
Novartis International AG /Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Pieris Pharmaceuticals Presents Clinical Data for Its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society of Hematology (Ash) Annual Meeting
BOSTON, MA--(Marketwired - December 07, 2015) - Pieris Pharmaceuticals, Inc

New Clinical Data on MorphoSys's Blood Cancer Drug Candidate MOR208 in NHL and CLL Presented at ASH Annual Meeting
MorphoSys AG /New Clinical Data on MorphoSys's Blood Cancer Drug Candidate MOR208 in NHL and CLL Presented at ASH Annual Meeting . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

MorphoSys Presents Interim Safety, Pharmacokinetic and Efficacy Data for MOR202 in Multiple Myeloma at ASH Meeting
MorphoSys AG /MorphoSys Presents Interim Safety, Pharmacokinetic and Efficacy Data for MOR202 in Multiple Myeloma at ASH Meeting . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations
Novartis International AG /Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
Novartis International AG /Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera
Novartis International AG /Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Trillium to Provide Update on CD47 Immune Checkpoint Inhibitor Program at the 2015 American Society of Hematology Annual Meeting
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor program targeting CD47 at the 57th Annual Meeting of the American Society of Hematology

Novimmune's Experimental Drug Selected for Oral Presentation at 2015 Annual Meeting of the American Society of Hematology (ASH)

Actinium Announces Strong Presence at 57th American Society of Hematology Annual Meeting December 4-8, 2015
NEW YORK, NY--(Marketwired - December 01, 2015) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers

Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research
Novartis International AG /Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Actinium Files Orphan Drug Application for Use of Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients
NEW YORK, NY--(Marketwired - November 23, 2015) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that it has filed an Application for Orphan Drug Designation with the U.S

Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for NINLARO® (ixazomib), First and Only Once-Weekly Oral Proteasome Inhibitor Recently Approved for Multiple Myeloma
Business Wire India

Takeda Reports Five-Year Overall Survival Data for ADCETRIS® (Brentuximab Vedotin) Demonstrate Durable Remissions in Relapsed/Refractory Hodgkin Lymphoma
Business Wire IndiaTakeda Pharmaceutical Company Limited (TSE:4502) announced post-treatment follow up data from the pivotal phase 2 study of single-agent brentuximab vedotin for the treatment of relapsed or refractory Hodgkin lymphoma following autologous stem cell transplantation (ASCT)

U.S. FDA Approves Takeda’s NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma
Business Wire IndiaTakeda Pharmaceutical Company Limited (TSE: 4502) today announced that the U.S

Regen BioPharma Presented Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at the American Society of Hematology Annual Meeting
Regen BioPharma Inc. (OTC PINK: RGBP) announced today it presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome at the American Society of Hematology Annual Meeting. This new drug target was identified by the Company's senior research consultant, Dr. Christine Ichim

Actinium's Scientific Advisory Board Endorses and Supports the Iomab-B Phase 3 Clinical Trial Development Program
SAN FRANCISCO, CA and NEW YORK, NY--(Marketwired - December 09, 2014) - Actinium Pharmaceuticals, Inc

Omni Bio Announces Encouraging Clinical Data for Use of Alpha-1 Antitrypsin (AAT) in Steroid-Resistant Graft Versus Host Disease
Omni Bio Pharmaceutical, Inc

Experts in Leukemia Treatment Support Ongoing Phase 1/2 Study of Actinium's Actimab-A, a Low Intensity Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Ages 60 and Older
SAN FRANCISCO, CA and NEW YORK, NY--(Marketwired - December 08, 2014) - Actinium Pharmaceuticals, Inc

Novartis announces safety and efficacy benefit of Jakavi® in global clinical trial of over 1,000 patients with myelofibrosis
Novartis International AG /Novartis announces safety and efficacy benefit of Jakavi® in global clinical trial of over 1,000 patients with myelofibrosis . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Six-year pivotal study data reinforce the superiority of Tasigna® over Glivec® in newly-diagnosed patients with Ph+ CML
Novartis International AG /Six-year pivotal study data reinforce the superiority of Tasigna® over Glivec® in newly-diagnosed patients with Ph+ CML . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

ADDITIONAL CLINICAL DATA FROM THE PHASE II STUDY WITH ABLYNX'S ANTI-vWF NANOBODY, CAPLACIZUMAB, PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
            

MorphoSys Presents Updated Phase 2 Clinical Results for MOR208 Monotherapy in NHL at American Society of Hematology Meeting
MorphoSys AG /MorphoSys Presents Updated Phase 2 Clinical Results for MOR208 Monotherapy in NHL at American Society of Hematology Meeting . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Phase III data shows Sandoz' investigational biosimilar filgrastim has similar safety and efficacy as Amgen's NEUPOGEN®
Novartis International AG /Phase III data shows Sandoz' investigational biosimilar filgrastim has similar safety and efficacy as Amgen's NEUPOGEN® . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia
Novartis International AG /Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014
Novartis International AG /Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Actinium Receives Orphan-Drug Designation From FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
NEW YORK, NY--(Marketwired - December 01, 2014) - Actinium Pharmaceuticals, Inc

Clinical data of Medigene's Dendritic Cell vaccines to be presented at ASH conference
Medigene AG /Clinical data of Medigene's Dendritic Cell vaccines to be presented at ASH conference . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers
For Non-US/Non-UK/Non-Canadian Media

Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
Seattle Genetics, Inc

Takeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients with Newly Diagnosed Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE:4502) today announced results from an open-label, Phase 2 study evaluating the safety and efficacy of oral, single-agent ixazomib (MLN9708) as maintenance therapy in patients with multiple myeloma (MM) who had received ixazomib, lenalidomide and dexamethasone as induction therapy

Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) has announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL)

Takeda Announces Formalization of Takeda Oncology to Enhance Discovery, Development and Global Commercialization of Breakthrough Cancer Medicines
Takeda Pharmaceutical Company Limited (TSE:4502) has announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda Oncology. The creation of Takeda Oncology will improve the company’s ability to meet the unique and urgent needs of cancer patients, their loved ones and health care providers worldwide

Takeda’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by U.S. FDA for Relapsed or Refractory Systemic Light-chain Amyloidosis
Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy status to the company’s investigational, oral proteasome inhibitor, ixazomib (MLN9708), for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis

Takeda Announces Abstracts for ADCETRIS® (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma and Ixazomib in Multiple Myeloma to be Presented at 56th American Society of Hematology Annual Meeting

Updated Data with Oral Proteasome Inhibitor MLN9708 Reported in Newly Diagnosed Multiple Myeloma Patients
Takeda Pharmaceutical Company Limited (TSE:4502) today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM)

Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
Seattle Genetics, Inc

New Data Presented at ASH Annual Meeting Enhance Understanding of PNH and aHUS to Provide Optimal Care for Patients with These Life-threatening Disorders
Alexion Pharmaceuticals, Inc

Novartis drug Jakavi® improved overall survival of patients with myelofibrosis in four separate analyses of long-term Phase III studies
Novartis International AG /Novartis drug Jakavi® improved overall survival of patients with myelofibrosis in four separate analyses of long-term Phase III studies . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Swedish Orphan Biovitrum AB (publ): New phase 3 data confirm long-lasting characteristics of rFIXFc and rFVIIIFc across multiple haemophilia populations
Interim analyses from phase 3 paediatric studies suggest prolonged half-life of investigational long-lasting therapies in children under age 12.

New five-year data support superiority of Novartis drug Tasigna® over Glivec® in newly diagnosed Ph+ CML patients
Novartis International AG /New five-year data support superiority of Novartis drug Tasigna® over Glivec® in newly diagnosed Ph+ CML patients . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
Novartis International AG /Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS
Novartis International AG /Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Sobi's partner Biogen Idec to present phase 3 data on prolonged half-life of Haemophilia candidates in young children at annual ASH meeting
Swedish Orphan Biovitrum AB's (publ ) (Sobi) partner Biogen Idec today announced that new data from their haemophilia clinical development and research programs will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), taking place in New Orleans, December 7-10

LEADING HEMATOLOGY JOURNAL PUBLISHES PIVOTAL ELOCTATE(TM) DATA THAT DEMONSTRATED EFFICACY AND SAFETY OF INVESTIGATIONAL LONG-LASTING THERAPY FOR HEMOPHILIA A
- Phase 3 Study Showed Potential for Once- or Twice-Weekly Prophylactic Dosing Regimens -

Xirrus Enables New Orleans Ernest N. Morial Convention Center to Provide and Sell High-Density Wireless Networks
Xirrus®, the leading provider of high-performance wireless networks, today announced the deployment of its Wireless Array solution at the newly renovated New Orleans Ernest N. Morial Convention Center, the sixth largest convention center in the United States, which includes 1.1 million square feet of contiguous exhibit space

MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 (Xmab5574)
MorphoSys AG /MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 (Xmab5574) . Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Aquilo Capital Management Submits Open Letter to the Board of Directors and Fellow Shareholders of Astex Pharmaceuticals
Dear members of the Board and fellow shareholders of Astex Pharmaceuticals, We are the Managing General Partner and Portfolio Manager of Aquilo Capital Management, a life science investment fund based in San Francisco. Our fund invests exclusively in small-cap biotech companies globally

ISCI Announces Medical & Laboratory Director
YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the Company) announced today that The Integrative Stem Cell Institute (ISCI), a premier provider of point-of-care, stem cell-based therapies, has announced the appointment of Dr Eduardo Cervera Ceballos, MD as its Medical and Laboratory Director.

Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
Novartis International AG /Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Novartis drug Exjade® approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia
Novartis International AG /Novartis drug Exjade® approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Two-year data show new Novartis drug Jakavi® significantly reduced myelofibrosis disease burden and suggest overall survival advantage
Novartis International AG /Two-year data show new Novartis drug Jakavi® significantly reduced myelofibrosis disease burden and suggest overall survival advantage . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved significantly deeper molecular response versus Glivec®
Novartis International AG /Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved significantly deeper molecular response versus Glivec® . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

SuppreMol's SM101 shows a sustained clinical activity and a favorable safety profile in Primary Immune Thrombocytopenia (ITP) patients
SuppreMol GmbH /SuppreMol's SM101 shows a sustained clinical activity and a favorable safety profile in Primary Immune Thrombocytopenia (ITP) patients . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
Novartis International AG /Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib and Oprozomib at 54th American Society of Hematology Annual Meeting
Onyx Pharmaceuticals, Inc

PropThink: Earnings Are Hardly the Focus of Pharmacyclics' Fiscal 1Q13 Financial Report
By Jake KingIn one of Monday's notable volume abnormalities, shares of Pharmacyclics (NASDAQ:PCYC) have exchanged hands at more than five times average volume, and PCYC is down 11% following the company's fiscal 1Q13 earnings release. Pharmacyclics beat estimates on revenues, $102.7M vs

PropThink: Earnings Are Hardly the Focus of Pharmacyclics' Fiscal 1Q13 Financial Report
By Jake King

MorphoSys Announces Presentation of Preclinical Data on MOR202 and MOR208 at 2012 American Society of Hematology Annual Meeting
MorphoSys AG /MorphoSys Announces Presentation of Preclinical Data on MOR202 and MOR208at2012 American Society of Hematology Annual Meeting. Processed andtransmitted by Thomson Reuters ONE.

MorphoSys and Xencor Report Clinical Data for MOR208/XmAb5574
MorphoSys AG /MorphoSys and Xencor Report Clinical Data for MOR208/XmAb5574. Processedand transmitted by Thomson Reuters ONE.

PropThink: Geron Q3 Earnings Review: Waiting Not for Godot, but for San Antonio and Atlanta
By Ivan DeryuginWhen a biotechnology company is around 20 years after its incorporation, common wisdom would suggest that it has become a major player in the biotechnology sector, with at least one blockbuster drug on the market. Alternate scenarios include either a takeover, or, if things do not work out as planned, bankruptcy. Geron (NASDAQ:GERN), however, has defied common wisdom

Onyx Pharmaceuticals Reports Third Quarter 2012 Financial Results

Novartis showcases ongoing research at ASCO to help patients fight various cancers, including updated data in advanced breast cancer
Novartis International AG /Novartis showcases ongoing research at ASCO to help patients fight various cancers, including updated data in advanced breast cancer . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Biostem U.S., Corporation Adds Jeanne Ann Lumadue, MD, PhD, MBA to Its Scientific and Medical Board of Advisors
Biostem U.S., Corporation, (OTCQB: HAIR) (PINKSHEETS: HAIR) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, today announced that Jeanne Ann Lumadue, MD, PhD, MBA, has been appointed to its Scientific and Medical Board of Advisors (SAMBA).

Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced the presentation of data from a phase 1 study investigating once a week MLN9708 in patients with relapsed or refractory systemic light-chain (AL) amyloidosis

Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results
For NON-US media only

Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin
For Non-US, Non-UK & Non-Canadian Media Only

Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 study
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) has reported data from a phase 1 / 2 study of once a week investigational MLN9708 in combination with standard dose lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM)

New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session
For Non-US, Non-UK & Non-Canadian Media Only

Novel compound shows promise for treating leukaemia
A novel anti-leukaemia compound has shown potential for becoming a new highly targeted therapy for humans - even for those resistant to conventional therapies, according to a new study.

REGENX BioSciences Highlights Gene Therapy Advances in the Prevention and Treatment of HIV and Hemophilia B Using NAV(TM) rAAV8 Vectors

Novartis pivotal study of Exjade® shows significant reduction of iron overload in patients with non-transfusion-dependent thalassemia
Novartis International AG /Novartis pivotal study of Exjade® shows significant reduction of iron overload in patients with non-transfusion-dependent thalassemia . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

New Phase III data shows Novartis JAK inhibitor INC424 significantly reduced disease burden in patients with myelofibrosis
Novartis International AG /New Phase III data shows Novartis JAK inhibitor INC424 significantly reduced disease burden in patients with myelofibrosis . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Two Novartis Phase III studies show twice as many Ph+ CML patients achieve deeper levels of response with Tasigna® compared to Glivec®
Novartis International AG /Two Novartis Phase III studies show twice as many Ph+ CML patients achieve deeper levels of response with Tasigna® compared to Glivec® . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Novartis highlights advances for patients with breast cancer and hematological diseases with over 160 SABCS and ASH abstracts
Novartis International AG /Novartis highlights advances for patients with breast cancer and hematological diseases with over 160 SABCS and ASH abstracts . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Biostem U.S. Corporation Expands Senior Management Team Recruiting Stem Cell Industry Veteran Dwight Brunoehler
Biostem U.S. Corporation (OTCQB: BOSM) (PINKSHEETS: BOSM), a leading developer of hair transplant technology using human stem cells, announced the addition of Dwight C. Brunoehler as Chief Executive Officer of the company.

'Trial' drug associated with 70pc response rate in chronic lymphocytic leukaemia
A novel experimental agent for chronic lymphocytic leukemia (CLL) has been found to be highly active and well tolerated in patients who have relapsed and are resistant to other therapy, according to an interim study.

Common blood clot in veins could lead to life-threatening condition
Results from a new study have revealed that patients with clinically diagnosed superficial vein thrombosis (SVT), a blood clot in the veins just beneath the skin that commonly resolves on its own without treatment, are at increased risk of developing venous thromboembolism (VTE), a dangerous, often life-threatening condition.

Soon! Patients in need of blood transfusion might become their own donors
A Paris-based research team has successfully injected cultured red blood cells (cRBCs) created from human hematopoietic stem cells (HSCs) into a human donor.

New drug for chronic leukaemia predicts who will respond to its effects
A new drug designed to treat chronic leukaemia has offered new markers that could identify which patients would receive maximum benefit from the treatment, according to researchers at Cleveland Clinic.

Comment on this story

Share